{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:58Z","timestamp":1793414158019,"version":"4.5.0"},"reference-count":73,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched PubMed and EMBASE up to 20 August 2020 to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of intensive care unit admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using a random-effects model. Thirty-four adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14 of 34 adult studies included only hospitalized patients). Risk of death among adult patients was 34% (95% CI, 28-39; N = 3240) in this sample of predominantly hospitalized patients. Patients aged \u226560 years had a significantly higher risk of death than patients &amp;lt;60 years (RR, 1.82; 95% CI, 1.45-2.27; N = 1169). The risk of death in pediatric patients was 4% (95% CI, 1-9; N = 102). RR of death comparing patients with recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.83-1.64; N = 736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients \u226560 years have significantly higher mortality; pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.<\/jats:p>","DOI":"10.1182\/blood.2020008824","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T16:57:31Z","timestamp":1603904251000},"page":"2881-2892","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":564,"title":["Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-1501","authenticated-orcid":false,"given":"Abi","family":"Vijenthira","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9306-2945","authenticated-orcid":false,"given":"Inna Y.","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-2295","authenticated-orcid":false,"given":"Thomas A.","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-0234","authenticated-orcid":false,"given":"Stephen","family":"Booth","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[{"name":"Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy;"},{"name":"Ca\u2019 Granda Ospedale Maggiore Policlinico, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-6731","authenticated-orcid":false,"given":"Fernando","family":"Mart\u00edn-Moro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ram\u00f3n y Cajal University Hospital, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Razanamahery","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Besan\u00e7on University Hospital, Besan\u00e7on, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Riches","sequence":"additional","affiliation":[{"name":"Centre for Hemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeff","family":"Zwicker","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christiane","family":"Vekemans","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cliniques Universitaires Saint-Luc, Universite\u0301 Catholique de Louvain (UCLouvain), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"Strategic Research Program on CLL, Universit\u00e0 Vita Salute and IRCCS Ospedale San Raffaele, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chatzikonstantinou","sequence":"additional","affiliation":[{"name":"HCT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-1638","authenticated-orcid":false,"given":"Halil","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Lattenist","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"},{"name":"Division of Hematology\/Oncology, St. Michael\u2019s Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020121716302261000_B1","article-title":"Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation [published online ahead of print 11 June 2020]","author":"Brissot","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"2020121716302261000_B2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2020121716302261000_B3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy [published correction appears in Bone Marrow Transplant. doi:10.1038\/s41409-020-0965-7, published online ahead of print 8 June 2020]","volume":"55","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2020121716302261000_B4","article-title":"Cancer patient management during the COVID-19 pandemic.","author":"ESMO"},{"key":"2020121716302261000_B5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/GO.20.00225","article-title":"Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data","volume":"6","author":"Giannakoulis","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2020121716302261000_B6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/GO.20.00097","article-title":"Covid-19 and cancer: lessons from a pooled meta-analysis","volume":"6","author":"Desai","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2020121716302261000_B7","article-title":"The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis [published online ahead of print 30 July 2020]","author":"ElGohary","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"5","key":"2020121716302261000_B8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.dsx.2020.07.037","article-title":"Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis","volume":"14","author":"Salunke","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"2020121716302261000_B9","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.jinf.2020.05.062","article-title":"Fatality rate of COVID-19 in patients with malignancies: a sytematic review and meta-analysis","volume":"81","author":"Afshar","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"2020121716302261000_B10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.46619\/Cmj.2020.3-1019","article-title":"COVID-19 and cancer patients","volume":"3","author":"Patel","year":"2020","journal-title":"Cancer Med J"},{"issue":"9","key":"2020121716302261000_B11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41375-020-0966-y","article-title":"Reply to \u201cCLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report\u201d Analysis of six hematological centers in Lombardy: on behalf of CLL commission of Lombardy Hematology Network (REL)","volume":"34","author":"Reda","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2020121716302261000_B12","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.16863","article-title":"Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia and COVID-19","volume":"190","author":"Thibaud","year":"2020","journal-title":"Br J Haematol"},{"issue":"21","key":"2020121716302261000_B13","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2020121716302261000_B14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid-Based Healthc"},{"key":"2020121716302261000_B15","first-page":"9","article-title":"Practical issues in calculating the sample size for prevalence studies","volume":"1","author":"Naing","year":"2006","journal-title":"Arch Orofac Sci"},{"issue":"3","key":"2020121716302261000_B16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.11124\/JBISRIR-2017-003798","article-title":"Incidence and prevalence of falls in adults with intellectual disability living in the community: a systematic review","volume":"17","author":"Ho","year":"2019","journal-title":"JBI Database Syst Rev Implement Reports"},{"key":"2020121716302261000_B17","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"issue":"11","key":"2020121716302261000_B18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"issue":"4","key":"2020121716302261000_B19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid-Based Healthc"},{"issue":"2","key":"2020121716302261000_B20","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16852","article-title":"Clinical outcome of coronavirus disease 2019 in haemato-oncology patients","volume":"190","author":"Aries","year":"2020","journal-title":"Br J Haematol"},{"key":"2020121716302261000_B21","doi-asserted-by":"crossref","first-page":"104574","DOI":"10.1016\/j.jcv.2020.104574","article-title":"Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - high mortality rate in infected patients with haematologic malignancies","volume":"130","author":"Biernat","year":"2020","journal-title":"J Clin Virol"},{"issue":"4","key":"2020121716302261000_B22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ejh.13469","article-title":"Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy","volume":"105","author":"Booth","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020121716302261000_B23","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/bjh.16874","article-title":"Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy","volume":"190","author":"Cook","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2020121716302261000_B24","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00277-020-04147-7","article-title":"COVID-19, impact on myeloma patients","volume":"99","author":"Dufour","year":"2020","journal-title":"Ann Hematol"},{"key":"2020121716302261000_B25","article-title":"Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany [published online ahead of print 30 July 2020]","author":"Engelhardt","journal-title":"Haematologica"},{"issue":"7","key":"2020121716302261000_B26","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41375-020-0877-y","article-title":"Reply to \u201cCOVID-19 in persons with haematological cancers\u201d: a focus on myeloid neoplasms and risk factors for mortality","volume":"34","author":"Fattizzo","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2020121716302261000_B27","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41375-020-0925-7","article-title":"Impact of Covid-19 on the treatment of acute myeloid leukemia","volume":"34","author":"Ferrara","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2020121716302261000_B28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bjh.17027","article-title":"Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy","volume":"191","author":"Fox","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2020121716302261000_B29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"2020121716302261000_B30","article-title":"COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers [published online ahead of print 16 October 2020]","author":"Hultcrantz","journal-title":"Blood Cancer Discov"},{"key":"2020121716302261000_B31","article-title":"COVID-19 in patients with hematological malignancies: a retrospective case series [published online ahead of print 4 August 2020]","author":"Infante","journal-title":"Int J Lab Hematol"},{"issue":"10241","key":"2020121716302261000_B32","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"2020121716302261000_B33","article-title":"COVID-19 in adult patients with hematological disease: analysis of clinical characteristics and outcomes [published online ahead of print 7 July 2020]","author":"Lattenist","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"10241","key":"2020121716302261000_B34","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"55","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2020121716302261000_B35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41409-020-0931-4","article-title":"COVID-19 outcomes in patients with hematologic disease","volume":"55","author":"Malard","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020121716302261000_B36","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/bjh.16801","article-title":"Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies","volume":"190","author":"Mart\u00edn-Moro","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2020121716302261000_B37","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2020121716302261000_B38","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"2020121716302261000_B39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(20)30238-2","article-title":"Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan","volume":"21","author":"Mei","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020121716302261000_B40","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"2020121716302261000_B41","article-title":"Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19 [published online ahead of print 21 July 2020]","author":"Patell","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020121716302261000_B42","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/j.jinf.2020.05.075","article-title":"Does type of immunosupression influence the course of Covid-19 infection?","volume":"81","author":"Razanamahery","year":"2020","journal-title":"J Infect"},{"issue":"10","key":"2020121716302261000_B43","first-page":"e737","article-title":"SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer","volume":"7","author":"Rugge","year":"2020","journal-title":"Nat Cancer"},{"key":"2020121716302261000_B44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3389\/fonc.2020.01279","article-title":"Factors affecting COVID-19 outcomes in cancer patients: a first report from Guy\u2019s Cancer Center in London","volume":"10","author":"Russell","year":"2020","journal-title":"Frontiers Oncol"},{"issue":"5","key":"2020121716302261000_B45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/ejh.13493","article-title":"Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies","volume":"105","author":"Sanchez-Pina","year":"2020","journal-title":"Eur J Haematol"},{"issue":"9","key":"2020121716302261000_B46","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2020121716302261000_B47","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King\u2019s College Hospital experience","volume":"190","author":"Shah","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2020121716302261000_B48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020121716302261000_B49","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/s41375-020-01019-x","article-title":"COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter","volume":"34","author":"Varma","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2020121716302261000_B50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2020121716302261000_B51","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"key":"2020121716302261000_B52","article-title":"The outcome of COVID-19 in patients with hematological malignancy [published online ahead of print 16 October 2020]","author":"Yigenoglu","journal-title":"J Med Virol"},{"key":"2020121716302261000_B53","article-title":"COVID-19 Registry Data Summaries","author":"American Society of Hematology (ASH) Research Collaborative"},{"key":"2020121716302261000_B54","article-title":"Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP [published online ahead of print 11 July 2020]","author":"Bisogno","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"7","key":"2020121716302261000_B55","doi-asserted-by":"crossref","first-page":"e28397","DOI":"10.1002\/pbc.28397","article-title":"COVID-19 infection in children and adolescents with cancer in Madrid","volume":"67","author":"de Rojas","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2020121716302261000_B56","doi-asserted-by":"crossref","first-page":"e28557","DOI":"10.1002\/pbc.28557","article-title":"Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic","volume":"67","author":"Faura","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020121716302261000_B57","doi-asserted-by":"crossref","first-page":"e28410","DOI":"10.1002\/pbc.28410","article-title":"Children with cancer in the time of COVID-19: an 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy","volume":"67","author":"Ferrari","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2020121716302261000_B58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/07853890.2020.1802061","article-title":"Characterisation of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis","volume":"52","author":"Wu","year":"2020","journal-title":"Ann Med"},{"issue":"16","key":"2020121716302261000_B59","doi-asserted-by":"crossref","first-page":"E5974","DOI":"10.3390\/ijerph17165974","article-title":"The age-related risk of severe outcomes due to COVID-19 Infection: a rapid review, meta-analysis, and meta-regression","volume":"17","author":"Romero Starke","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2020121716302261000_B60","article-title":"SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings [published online ahead of print 19 August 2020]","author":"Williams","journal-title":"Pathology"},{"issue":"9","key":"2020121716302261000_B61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","article-title":"Case characteristics, resource use, and outcomes of 10\u2008021 patients with COVID-19 admitted to 920 German hospitals: an observational study","volume":"8","author":"Karagiannidis","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"20","key":"2020121716302261000_B62","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"issue":"30","key":"2020121716302261000_B63","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020121716302261000_B64","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40265-020-01367-z","article-title":"Pharmaco-immunomodulatory therapy in COVID-19","volume":"80","author":"Rizk","year":"2020","journal-title":"Drugs"},{"key":"2020121716302261000_B65","article-title":"Racial disparities in COVID-19 hospitalization and in-hospital mortality at the height of the New York city pandemic [published online ahead of print 18 September 2020]","author":"Renelus","journal-title":"J Racial Ethn Health Disparities"},{"issue":"4","key":"2020121716302261000_B66","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jrh.12511","article-title":"COVID-19 death rates are higher in rural counties with larger shares of Blacks and Hispanics","volume":"36","author":"Cheng","year":"2020","journal-title":"J Rural Health"},{"issue":"10242","key":"2020121716302261000_B67","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","article-title":"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis","volume":"395","author":"Chu","year":"2020","journal-title":"Lancet"},{"key":"2020121716302261000_B68","article-title":"COVID-19 in pediatric cancer patients in a resource-limited setting: national data from Peru [published online ahead of print 22 July 2020]","author":"Montoya","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2020121716302261000_B69","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cancers12071841","article-title":"Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe","volume":"12","author":"Pinato","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2020121716302261000_B70","article-title":"Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients [published online ahead of print 11 June 2020]","author":"Pinato","journal-title":"Cancer Discov"},{"issue":"8","key":"2020121716302261000_B71","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"2020121716302261000_B72","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41375-020-0960-4","article-title":"Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands","volume":"34","author":"van Doesum","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2020121716302261000_B73","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2020006854","article-title":"Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a campus CLL report","volume":"136","author":"Cuneo","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/25\/2881\/1794641\/bloodbld2020008824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/25\/2881\/1794641\/bloodbld2020008824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:09:53Z","timestamp":1618099793000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/25\/2881\/469789\/Outcomes-of-patients-with-hematologic-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":73,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,12,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008824","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]}}}